Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It

ConferencePositive

AI Analysis

Summary

Acclinate, which previously modernized clinical trial diversity at DPHARM in 2022, returns to the conference with a new platform designed to help pharmaceutical companies analyze and act on community data.

Importance:2/10

Sentiment:

0.50

clinical_trial_diversitypatient_communitiesdata_platformconference

Related Companies

$CHCT

Read the original article

Published by PR Newswire Clinical Trials on September 14, 2026 12:34 PM

Read Original